Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin
Identifieur interne : 000293 ( Main/Exploration ); précédent : 000292; suivant : 000294Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin
Auteurs : RBID : ISTEX:259_1992_Article_BF00177053.pdfEnglish descriptors
- KwdEn :
Abstract
A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3–5 days later by 100–150 μg of indium-111 streptavidin, at the specific activity of 280–370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1–8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1–30:1) and 45:1 (range 12:1–120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1–30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01–0.3) for recurrences and 0.05 for primary tumour (range 0.005–0.2). Over 24–48 h 14% i.d. (range 8–18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56–70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.
DOI: 10.1007/BF00177053
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin</title><author><name>Giovanni Paganelli</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Carlo Belloni</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Patrizia Magnani</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Felicia Zito</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Andrea Pasini</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Isabella Sassi</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Mario Meroni</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Massimo Mariani</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Mario Vignali</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Antonio G. Siccardi</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author><author><name>Ferruccio Fazio</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan</wicri:regionArea><wicri:noRegion>Milan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1992_Article_BF00177053.pdf</idno><date when="1992">1992</date><idno type="doi">10.1007/BF00177053</idno><idno type="wicri:Area/Main/Corpus">000116</idno><idno type="wicri:Area/Main/Curation">000116</idno><idno type="wicri:Area/Main/Exploration">000293</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Intraperitoneal injection</term><term>Monoclonal antibody</term><term>Radioactive streptavidin</term><term>Tumour pretargetting</term><term>Two-step</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3–5 days later by 100–150 μg of indium-111 streptavidin, at the specific activity of 280–370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1–8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1–30:1) and 45:1 (range 12:1–120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1–30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01–0.3) for recurrences and 0.05 for primary tumour (range 0.005–0.2). Over 24–48 h 14% i.d. (range 8–18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56–70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="140888a1f32dea59d362889d22cc850f222e921d"><titleInfo lang="eng"><title>Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin</title></titleInfo><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Paganelli</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Belloni</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Patrizia</namePart><namePart type="family">Magnani</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Felicia</namePart><namePart type="family">Zito</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Andrea</namePart><namePart type="family">Pasini</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Isabella</namePart><namePart type="family">Sassi</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Mario</namePart><namePart type="family">Meroni</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Massimo</namePart><namePart type="family">Mariani</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Mario</namePart><namePart type="family">Vignali</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Antonio G.</namePart><namePart type="family">Siccardi</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><name type="personal"><namePart type="given">Ferruccio</namePart><namePart type="family">Fazio</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, INB-CNR, Università di Milano, via Olgettina 60, I-20132, Milan, Italy</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1991-12-14</dateCreated><dateValid encoding="w3cdtf">2004-07-05</dateValid><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3–5 days later by 100–150 μg of indium-111 streptavidin, at the specific activity of 280–370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1–8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1–30:1) and 45:1 (range 12:1–120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1–30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01–0.3) for recurrences and 0.05 for primary tumour (range 0.005–0.2). Over 24–48 h 14% i.d. (range 8–18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56–70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.</abstract><subject lang="eng"><genre>Key words</genre><topic>Two-step</topic><topic>Tumour pretargetting</topic><topic>Monoclonal antibody</topic><topic>Intraperitoneal injection</topic><topic>Radioactive streptavidin</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1992</partNumber><partNumber>Volume: 19</partNumber><partNumber>Number: 5</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1992-05-01</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 14</identifier><recordInfo><recordOrigin>Springer-Verlag, 1992</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00177053</identifier><identifier type="matrixNumber">Art3</identifier><identifier type="local">BF00177053</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>322</start><end>329</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1992</recordOrigin><recordIdentifier>259_1992_Article_BF00177053.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000293 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000293 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1992_Article_BF00177053.pdf
|texte= Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin
}}
| This area was generated with Dilib version V0.5.81. |  |